Paratek Pharmaceuticals

Paratek Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics based upon tetracycline chemistry. The company creates chemically diverse and biologically distinct small molecules derived from the minocycline core structure. The company's two key product candidates are: antibacterials omadacycline, an aminomethylcycline antibiotics for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infection, and other bacterial infections; and sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
  • TickerPRTK
  • ISINUS6993743029
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Robert Driscoll

Q2 Financials; Nuzyra Launch Picking Up Steam

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

A director sold 3,000 shares at 14.220USD and

A director at Paratek Pharmaceuticals Inc sold 3,000 shares at 14.220USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The na...

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

ValuEngine Rating and Forecast Report for PRTK

ResearchPool Subscriptions

Get the most out of your insights

Get in touch